ArticleMedicine2026
Trends and mortality due to acute respiratory distress syndrome in the United States (1999-2023): A 25-year nationwide study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) remains a significant cause of morbidity and mortality in the United States. Although advances in critical care have improved outcomes, the Coronavirus Disease of 2019 (COVID-19) pandemic substantially altered ARDS epidemiology, necessitating updated analyses of national mortality trends. To examine 25-year trends (1999-2023) in ARDS-related mortality across demographic, geographic, and urbanization categories, and to evaluate the impact of the COVID-19 pandemic on these patterns. We conducted a population-based descriptive study using CDC WONDER multiple cause-of-death data. ARDS-related deaths were identified by ICD-10 code J80. Crude and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal changes were analyzed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals. Mortality rates were stratified by sex, age, race/ethnicity, census region, state, and urban-rural classification. Between 1999 and 2023, 364,924 ARDS-related deaths were recorded. National AAMRs declined steadily from 1999 to 2018 (APC -2.63; 95% confidence interval (CI): -4.74--1.04), surged sharply during 2018 to 2021 (APC 85.78; 95% CI: 53.65-109.16), and decreased between 2021 and 2023 (APC -59.59; 95% CI: -68.58--47.89), resulting in an overall AAPC of -1.90 (95% CI: -3.80-0.19). Males consistently exhibited higher mortality rates than females. Individuals aged ≥ 75 years had the highest AAMRs. Non-Hispanic Black, Hispanic/Latino, and American Indian/Alaska Native populations experienced disproportionately elevated mortality. Rural areas and the South and Midwest regions showed greater increases during the pandemic. California, Texas, Florida, and New York reported the highest cumulative death counts. ARDS mortality in the United States declined for nearly 2 decades but rose sharply during the COVID-19 pandemic, highlighting persistent disparities by age, sex, race, geography, and urbanization. Targeted interventions and equitable critical care access are essential to reduce future ARDS-related deaths. Detailed Visual Abstract is illustrated in the Central Illustration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.